Suven Life Sciences will present the portfolio of investigational neuroscience new chemical entities (NCEs) at Alzheimer's conference (ICAD) to be held at Chicago USA from July 27 to 31, 2008. ICAD is the bi-annual conference of the Alzheimer's association and more than ten thousand neuro scientists, clinicians, corporate from all over the world covering all the major pharma and academic research institutions are expected to attend the meeting.

According to the company, it would present the key biology data in animal models of cognition and brain micro dialysis on SUVN-502, a potent, selective, brain penetrant and orally active 5-HT6 receptor antagonist for the symptomatic treatment of Alzheimer's disease. Scientists from the company will also present paper on new animal model for Alzheimer's disease with dual blockade of cholinergic and glutametergic neural system induced memory impairment in rats. Alzheimer's disease has a significant unmet medical need for which current treatment options are insufficient. Suven has a number of discovery programs in the area of cognition, focusing on novel approaches that may lead to the development of new therapies for patients.

The company added that it is committed to neuroscience research and development of new treatments for neurological disorders. Suven's discovery research focuses on central nervous system (CNS) disorders through novel mechanisms using small-molecule medicinal chemistry approaches. Its CNS drug discovery scientists are pursuing innovative ways to develop treatments for a variety of CNS disorders like Alzheimer's, schizophrenia, depression, cognitive disorders, sleep, neuro degeneration and obesity through CNS targets.